#USA #Glendale #MolecuLight #fluorescence imaging #Dr. Michael Desvigne

MolecuLight's Innovations in Reconstructive Surgery

MolecuLight Inc., a pioneering force in point-of-care fluorescence imaging technologies, has announced a significant presentation by Dr. Michael N. Desvigne, a prominent plastic surgeon, at the upcoming 47th Annual JAB Maui Burn & Wound Symposium. This event is scheduled to take place from January 25 to 30, 2025. The symposium is renowned for gathering experts and professionals dedicated to advancing techniques in wound healing and burn treatment.

Dr. Desvigne's session will focus on the clinical benefits of MolecuLight's imaging technology, particularly how it contributes to improved infection management and enhances surgical procedures in soft tissue reconstruction. His research encapsulates a series of successful implementations of the MolecuLight platform, demonstrating substantial improvements in surgical outcomes and patient recovery timelines, especially in complex cases that involve grafts, flaps, or skin substitutes.

As an accomplished fellow of the American College of Surgeons, Dr. Desvigne is actively involved with a multidisciplinary team at the Abrazo Arrowhead Hospital and Wound Clinic in Glendale, Arizona. This collaborative team includes a diverse array of healthcare professionals such as wound care specialists, hospital physicians, internists, nurses, and various surgical experts. Their collective expertise, combined with the advanced capabilities of MolecuLight's technology, aims to drive significant improvements in managing wound infections and performing reconstructive surgery.

During the symposium, Dr. Desvigne will present his compelling findings, which highlight the profound impact of real-time visualization of bacterial infections using MolecuLight’s fluorescence imaging technology. He notes that the ability to identify infections instantaneously has drastically transformed clinical practices, enabling healthcare providers to make more informed treatment decisions in real time. This, in turn, fosters faster healing processes and contributes to cost-effective care solutions for patients.

Dr. Desvigne expressed his enthusiasm about sharing these insights at the prestigious conference: "The potential to visualize bacterial infections as they occur has revolutionized our clinical approach. It allows us to tailor our treatment strategies to meet the specific needs of each surgical case, ultimately enhancing both patient outcomes and recovery speeds. I am looking forward to discussing these advancements with my peers at the JAB Maui Symposium and continuing to push forward the field of wound care."

Anil Amlani, CEO of MolecuLight, also shared his excitement regarding Dr. Desvigne's presentation. “We take pride in having Dr. Desvigne share his significant research and clinical experiences with our technology at the JAB Maui Burn & Wound Symposium. His presentations will illustrate how our fluorescence imaging technology is changing infection management and improving patient outcomes across various surgical domains. Better health outcomes lead not only to enhanced patient satisfaction but also to lower overall healthcare costs.”

The fluorescence imaging technology developed by MolecuLight is recognized globally for its capability to detect and visualize bacterial infections in real time. By providing clinicians with invaluable insights, it facilitates more accurate treatment decisions and expedites healing processes. Dr. Desvigne's extensive application of the MolecuLight platform underscores its potential to enhance results for patients undergoing intricate wound care and surgical procedures.

About MolecuLight Inc.

MolecuLight Inc. is a privately held medical imaging company with a global reach. It manufactures and distributes the MolecuLight iX® and DX™ imaging devices, which are the only FDA-approved point-of-care imaging devices classified as Class II for the real-time detection of elevated bacterial burdens in wounds. These devices also provide precise digital wound measurement for comprehensive wound management, supported by robust clinical evidence, including over 100 peer-reviewed publications.

For inquiries related to sales, media, or further information, please contact Hunter Zudans, Marketing Director at MolecuLight Inc., via telephone at +1.484.682.7580 or email at [email protected]. More information can be accessed on their website: www.molecuight.com.